UB Paderborn / Katalog / Suche / in CDI

Clonal Dissemination of a CTX-M-15 β-Lactamase-Producing Escherichia coli Strain in the Paris Area, Tunis, and Bangui

Antimicrobial Agents and Chemotherapy, 2006-07, Vol.50 (7), p.2433-2438

2006

Volltextzugriff (PDF)

Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

Annals of oncology, 2018-10, Vol.29, p.viii251-viii251

2018

Volltextzugriff (PDF)

4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2

European journal of cancer (1990), 2014-11, Vol.50, p.8-8

2014

Volltextzugriff (PDF)

PCN42 - Estimation Of Incidence Of Pancreatic Cancer By State And By Age Group In The United States

Value in health, 2016-05, Vol.19 (3), p.A141-A141

2016

Volltextzugriff (PDF)

Estimation Of Incidence Of Pancreatic Cancer By State And By Age Group In The United States

Value in health, 2016-05, Vol.19 (3), p.A141-A141

2016

Volltextzugriff (PDF)

Evaluation of a cefoxitin disk diffusion test for the routine detection of methicillin-resistant Staphylococcus aureus

Clinical microbiology and infection, 2004-08, Vol.10 (8), p.762-765

2004

Volltextzugriff (PDF)

PCN58 - Budget Impact Analysis of Nanoliposomal Irinotecan for Treatment of Pancreatic Cancer Following Progression on Gemcitabine - A Us Payer Perspective

Value in health, 2016-11, Vol.19 (7), p.A718-A719

2016

Volltextzugriff (PDF)

Budget Impact Analysis of Nanoliposomal Irinotecan for Treatment of Pancreatic Cancer Following Progression on Gemcitabine - A Us Payer Perspective

Value in health, 2016-11, Vol.19 (7), p.A718-A719

2016

Volltextzugriff (PDF)

IMPUTING MISSING VALUES TO ESTIMATE HEALTH-RELATED QUALITY OF LIFE (HR-QOL) IN METASTATIC PANCREATIC CANCER (MPC) TREATED WITH 5-FLUOROURACIL AND LEUCOVORIN, WITH AND WITHOUT LIPOSOMAL IRINOTECAN (NAL-IRI)

Value in health, 2017-05, Vol.20 (5), p.A119

2017

Volltextzugriff (PDF)

MULTIVARIATE ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE (HR-QOL) IN METASTATIC PANCREATIC CANCER (MPC) TREATED WITH 5- FLUOROURACIL AND LEUCOVORIN, WITH AND WITHOUT LIPOSOMAL IRINOTECAN (NAL-IRI)

Value in health, 2017-05, Vol.20 (5), p.A120

2017

Volltextzugriff (PDF)

Modification of the Bu Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring

Bone marrow transplantation (Basingstoke), 2005-04, Vol.35 (8), p.747-754

2005

Volltextzugriff (PDF)

Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study

Annals of oncology, 2016-09, Vol.27, p.iv18

2016

Volltextzugriff (PDF)

CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Annals of oncology, 2017-11, Vol.28, p.x66-x67

2017

Volltextzugriff (PDF)

Evolution of acquired resistance to third-generation cephalosporins in Enterobacteriaceae in a Tunisian hospital 1993–2001

Clinical microbiology and infection, 2004-07, Vol.10 (7), p.665-667

2004

Volltextzugriff (PDF)

Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: a phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy

Annals of oncology, 2017-11, Vol.28, p.x67-x68

2017

Volltextzugriff (PDF)

242P Effects of nal-IRI (MM-398) 6 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1

Annals of oncology, 2016-12, Vol.27, p.ix76-ix76

2016

Volltextzugriff (PDF)

242P Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1

Annals of oncology, 2016-12, Vol.27 (suppl_9)

2016

Volltextzugriff (PDF)

PD-023Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Annals of oncology, 2016-06, Vol.27 (Suppl 2), p.ii110-ii110

2016

Volltextzugriff (PDF)

O-004Effects of nal-IRI (MM-398) plus or minus 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii119-ii119

2016

Volltextzugriff (PDF)

PD-023Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) plus or minus 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii110-ii110

2016

Volltextzugriff (PDF)

O-004 Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine

Annals of oncology, 2016-06, Vol.27, p.ii119

2016

Volltextzugriff (PDF)

PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Annals of oncology, 2016-06, Vol.27, p.ii110

2016

Volltextzugriff (PDF)

Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Annals of oncology, 2016-10, Vol.27, p.vi234-vi234

2016

Volltextzugriff (PDF)

Quantification of viable Brochothrix thermosphacta in cooked shrimp and salmon by real-time PCR

Food microbiology, 2012-05, Vol.30 (1), p.173-179

2012

Volltextzugriff (PDF)

735PReal-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Clonal Dissemination of a CTX-M-15 β-Lactamase-Producing Escherichia coli Strain in the Paris Area, Tunis, and Bangui

Real-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2

PCN42 - Estimation Of Incidence Of Pancreatic Cancer By State And By Age Group In The United States

Estimation Of Incidence Of Pancreatic Cancer By State And By Age Group In The United States

Evaluation of a cefoxitin disk diffusion test for the routine detection of methicillin-resistant Staphylococcus aureus

PCN58 - Budget Impact Analysis of Nanoliposomal Irinotecan for Treatment of Pancreatic Cancer Following Progression on Gemcitabine - A Us Payer Perspective

Budget Impact Analysis of Nanoliposomal Irinotecan for Treatment of Pancreatic Cancer Following Progression on Gemcitabine - A Us Payer Perspective

IMPUTING MISSING VALUES TO ESTIMATE HEALTH-RELATED QUALITY OF LIFE (HR-QOL) IN METASTATIC PANCREATIC CANCER (MPC) TREATED WITH 5-FLUOROURACIL AND LEUCOVORIN, WITH AND WITHOUT LIPOSOMAL IRINOTECAN (NAL-IRI)

MULTIVARIATE ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE (HR-QOL) IN METASTATIC PANCREATIC CANCER (MPC) TREATED WITH 5- FLUOROURACIL AND LEUCOVORIN, WITH AND WITHOUT LIPOSOMAL IRINOTECAN (NAL-IRI)

Modification of the Bu Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring

Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study

CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Evolution of acquired resistance to third-generation cephalosporins in Enterobacteriaceae in a Tunisian hospital 1993–2001

Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: a phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy

242P Effects of nal-IRI (MM-398) 6 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1

242P Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine based therapy: Results from NAPOLI-1

PD-023Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

O-004Effects of nal-IRI (MM-398) plus or minus 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine

PD-023Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) plus or minus 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

O-004 Effects of nal-IRI (MM-398) ± 5-fluorouracil on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine

PD-023 Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Quantification of viable Brochothrix thermosphacta in cooked shrimp and salmon by real-time PCR

735PReal-world dosing patterns of patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in US oncology clinics

Aktive Filter

Suchergebnisse filtern